)
Akums Drugs and Pharmaceuticals (AKUMS) investor relations material
Akums Drugs and Pharmaceuticals Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 FY26 delivered strong operating performance with robust execution across key segments, especially CDMO, and improved international and domestic branded formulation businesses.
International branded formulation business rebounded due to demand recovery in key markets.
API and trade generics segments continued to face pressure but showed sequential improvement through portfolio rationalization and cost controls.
Strategic projects in Europe and Zambia are progressing, with regulatory milestones achieved and commercial supplies expected in coming years.
Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with no qualifications reported.
Financial highlights
Q3 FY26 consolidated revenue from operations was ₹11,595.87 million, up from ₹10,104.11 million in Q3 FY25; consolidated profit for Q3 FY26 was ₹676.74 million.
Operating EBITDA reached ₹1,470 million, up 21% year-on-year and 55.4% quarter-on-quarter; EBITDA margin improved to 12.7%.
Q3 FY26 consolidated total income rose 16.5% YoY to ₹11,940 million; PAT up 2.1% YoY to ₹680 million.
One-time labor code impact of ₹182.28 million included as an exceptional item.
EPS (consolidated) for Q3 FY26 was ₹4.33, up from ₹2.66 in Q3 FY25.
Outlook and guidance
Double-digit volume growth in CDMO expected to sustain in Q4, with strong visibility for near-term performance.
Zambia and EU projects to contribute significant revenues in coming years, with Zambia supplies starting H1 FY27 and EU commercial supplies expected in FY28.
Management remains focused on long-term growth drivers: innovation, operational efficiency, cost control, and strategic partnerships.
Strategic investment made in Akums Healthcare Malta Private Limited to expand European operations.
Next Akums Drugs and Pharmaceuticals earnings date
Next Akums Drugs and Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)